A young patient holds Kalydeco, a cystic-fibrosis treatment from Vertex just approved by the FDA.
Certain cystic-fibrosis patients will now have an FDA-approved treatment that targets an underlying cause of their disease.
But that drug — Kalydeco, from Vertex Pharmaceuticals — won’t come cheap.
As Dow Jones Newswires reports, the annual cost will be $294,000. Vertex has set up a patient-assistance program to help patients pay for the treatment.
Comments
To add a comment to the original post, click here.
You must be signed in to post a comment.
Sign in nowThere are no comments for this post.